Biodegradable-polymer stents versus durable-polymer stents - Authors' reply

Affiliations

¹ Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON M5B 1W8, Canada; Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. Electronic address: peter.juni@utoronto.ca.
² Institute of Social and Preventive Medicine and Clinical Trials Unit, University Hospital, Bern, Switzerland.
³ Department of Cardiology, Swiss Cardiovascular Center, University Hospital, Bern, Switzerland.

Comment

Peter Jüni et al. Lancet. 2019.

. 2019 May 11;393(10184):1933.

doi: 10.1016/S0140-6736(19)30032-7.

¹ Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON M5B 1W8, Canada; Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. Electronic address: peter.juni@utoronto.ca.
² Institute of Social and Preventive Medicine and Clinical Trials Unit, University Hospital, Bern, Switzerland.
³ Department of Cardiology, Swiss Cardiovascular Center, University Hospital, Bern, Switzerland.

No abstract available

Comment on

Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.
Pilgrim T, Heg D, Roffi M, Tüller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Fahrni T, Moschovitis A, Noble S, Eberli FR, Wenaweser P, Jüni P, Windecker S. Pilgrim T, et al. Lancet. 2014 Dec 13;384(9960):2111-22. doi: 10.1016/S0140-6736(14)61038-2. Epub 2014 Sep 1. Lancet. 2014. PMID: 25189359 Clinical Trial.